JP2007031434A - ストレプトグラミン誘導体 - Google Patents
ストレプトグラミン誘導体 Download PDFInfo
- Publication number
- JP2007031434A JP2007031434A JP2006201006A JP2006201006A JP2007031434A JP 2007031434 A JP2007031434 A JP 2007031434A JP 2006201006 A JP2006201006 A JP 2006201006A JP 2006201006 A JP2006201006 A JP 2006201006A JP 2007031434 A JP2007031434 A JP 2007031434A
- Authority
- JP
- Japan
- Prior art keywords
- pristinamycin
- general formula
- streptogramin
- ethyl
- periodate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010034396 Streptogramins Proteins 0.000 title claims abstract description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000017858 demethylation Effects 0.000 claims description 4
- 238000010520 demethylation reaction Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 6
- 230000003115 biocidal effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 20
- 108010079780 Pristinamycin Proteins 0.000 description 20
- RLNUPSVMIYRZSM-UHFFFAOYSA-N Pristinamycin Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)CCN(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O RLNUPSVMIYRZSM-UHFFFAOYSA-N 0.000 description 20
- 229960003961 pristinamycin Drugs 0.000 description 20
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 20
- JOOMGSFOCRDAHL-XKCHLWDXSA-N pristinamycin-IIB Natural products CC(C)[C@@H]1OC(=O)[C@H]2CCCN2C(=O)c3coc(CC(=O)C[C@@H](O)C=C(C)C=CCNC(=O)C=C[C@H]1C)n3 JOOMGSFOCRDAHL-XKCHLWDXSA-N 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- PCOXSOQWQVRJCH-RIECGXCRSA-N efepristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(NC)=CC=2)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PCOXSOQWQVRJCH-RIECGXCRSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- PYVXLMQALOZKES-UHFFFAOYSA-M tetrabutylazanium;periodate Chemical compound [O-]I(=O)(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC PYVXLMQALOZKES-UHFFFAOYSA-M 0.000 description 4
- PCOXSOQWQVRJCH-UHFFFAOYSA-N vernamycin-Bbeta Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(NC)=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O PCOXSOQWQVRJCH-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- BYRKDHSWMQLYJB-UHFFFAOYSA-N pristinamycin IC Chemical compound CN1C(=O)C2CCCN2C(=O)C(C)NC(=O)C(NC(=O)C=2C(=CC=CN=2)O)C(C)OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C1CC1=CC=C(N(C)C)C=C1 BYRKDHSWMQLYJB-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- HXDLWJWIAHWIKI-UHFFFAOYSA-N 2-hydroxyethyl acetate Chemical compound CC(=O)OCCO HXDLWJWIAHWIKI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241001625939 Pristina Species 0.000 description 1
- YGXCETJZBDTKRY-UHFFFAOYSA-N Pristinamycin Component I A Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)N(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010015795 Streptogramin B Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- CKARQVRBPFIZCR-UHFFFAOYSA-N vernamycin-b delta Chemical compound C1=CC(NC)=CC=C1CC1C(=O)N2CCC(=O)CC2C(=O)NC(C=2C=CC=CC=2)C(=O)OC(C)C(NC(=O)C=2C(=CC=CN=2)O)C(=O)NC(C)C(=O)N2CCCC2C(=O)N1C CKARQVRBPFIZCR-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
R1はメチルまたはエチル基を表し、R2は水素原子を表し、そしてX及びYは一緒になってオキソ基を形成するか、あるいは、R1はエチル基を表し、R2及びXは水素原子を表し、そしてYは水素原子またはヒドロキシル基を表すか、あるいは、R1はエチル基を表し、R2はヒドロキシル基を表し、そしてX及びYは一緒になってオキソ基を形成する、
で示されるストレプトグラミンの一部(B群の化合物)は、A群の成分と組み合わせた場合、殺菌作用の相乗効果をもたらす。かようなストレプトグラミンは、一般式(II)
Tet.Lett.,18、1567(1977) J.Org.Chem.,49、2795(1984) J.C.S.Chem.Comm.,905(1989) Tet.Lett.,33、6991(1992)
19g)を、1460cm3のジクロロメタン、500cm3の酢酸、及び40cm3のエチレングリコールの混合物中、三首フラスコ中で、溶液中に置く。温度を30℃に保ちながら、97.5gの過ヨウ素酸テトラ−n−ブチルアンモニウムを加える。30℃で3時間撹拌後、撹拌しながら、34.7gのヒドロキシルアミン塩酸塩を含んでいる2000cm3の脱塩水を添加することにより反応を停止する。水相を沈降させ、次に分離して除く。有機相を2000cm3の水で洗浄する。沈降及び分離後、有機相をシロップに濃縮する。この濃縮物に2500cm3の酢酸エチルを注ぎ、そして次に、この溶液を1300cm3の最終容量に濃縮する。この懸濁液を5℃で濾過する。結晶を400cm3の新しい酢酸エチルで3回洗浄し、そして1500Paの残留圧(residual pressure)下で40℃で乾燥させる。このようにして、91%のプリスチナマイシンIBアッセイを与える331gの白色の生成物を得る。
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9504585A FR2733236B1 (fr) | 1995-04-18 | 1995-04-18 | Procede de preparation de streptogramines |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53151096A Division JP3856342B2 (ja) | 1995-04-18 | 1996-04-16 | ストレプトグラミンの製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007031434A true JP2007031434A (ja) | 2007-02-08 |
Family
ID=9478183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53151096A Expired - Fee Related JP3856342B2 (ja) | 1995-04-18 | 1996-04-16 | ストレプトグラミンの製造方法 |
| JP2006201006A Pending JP2007031434A (ja) | 1995-04-18 | 2006-07-24 | ストレプトグラミン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53151096A Expired - Fee Related JP3856342B2 (ja) | 1995-04-18 | 1996-04-16 | ストレプトグラミンの製造方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5789537A (ja) |
| EP (1) | EP0821697B1 (ja) |
| JP (2) | JP3856342B2 (ja) |
| KR (1) | KR19990007800A (ja) |
| CN (1) | CN1181758A (ja) |
| AP (1) | AP768A (ja) |
| AR (1) | AR002291A1 (ja) |
| AT (1) | ATE194991T1 (ja) |
| AU (1) | AU708419B2 (ja) |
| BR (1) | BR9604927A (ja) |
| CA (1) | CA2215991A1 (ja) |
| CZ (1) | CZ285798B6 (ja) |
| DE (1) | DE69609499T2 (ja) |
| DK (1) | DK0821697T3 (ja) |
| EA (1) | EA000350B1 (ja) |
| EG (1) | EG20782A (ja) |
| ES (1) | ES2148759T3 (ja) |
| FR (1) | FR2733236B1 (ja) |
| GR (1) | GR3033873T3 (ja) |
| HU (1) | HUP9802942A3 (ja) |
| IL (1) | IL117968A (ja) |
| IN (1) | IN185120B (ja) |
| NO (1) | NO974747D0 (ja) |
| NZ (1) | NZ307236A (ja) |
| OA (1) | OA10525A (ja) |
| PL (1) | PL322822A1 (ja) |
| PT (1) | PT821697E (ja) |
| SK (1) | SK140497A3 (ja) |
| TR (1) | TR199701204T1 (ja) |
| TW (1) | TW334437B (ja) |
| WO (1) | WO1996033213A1 (ja) |
| ZA (1) | ZA963102B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1204676B1 (fr) * | 1999-07-27 | 2003-10-22 | Aventis Pharma S.A. | Derives de streptogramines, leur preparation et les compositions qui les contiennent |
| FR2796950B1 (fr) * | 1999-07-27 | 2001-09-21 | Aventis Pharma Sa | Derives de streptogramines, leur preparation et les compositions qui les contiennent |
| FR2796949B1 (fr) | 1999-07-27 | 2001-09-21 | Aventis Pharma Sa | Derives de streptogramines, leur preparation et les compositions qui les contiennent |
| KR20070027290A (ko) * | 2005-09-06 | 2007-03-09 | 엘지이노텍 주식회사 | 발광 소자 및 그 제조 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2664894A1 (fr) * | 1990-07-19 | 1992-01-24 | Rhone Poulenc Sante | Nouveaux derives de streptogramines et leur preparation. |
| FR2689518B1 (fr) * | 1992-04-01 | 1995-04-07 | Rhone Poulenc Rorer Sa | Microorganismes, procédé de préparation et utilisation. |
| IL121821A (en) * | 1993-02-17 | 2000-02-17 | Rhone Poulenc Rorer Sa | Process for purifying a group A minority component of streptogramin some such purified components and their uses |
-
1995
- 1995-04-18 FR FR9504585A patent/FR2733236B1/fr not_active Expired - Fee Related
-
1996
- 1996-04-16 AT AT96913594T patent/ATE194991T1/de not_active IP Right Cessation
- 1996-04-16 KR KR1019970707323A patent/KR19990007800A/ko not_active Withdrawn
- 1996-04-16 CZ CZ973290A patent/CZ285798B6/cs not_active IP Right Cessation
- 1996-04-16 EG EG32896A patent/EG20782A/xx active
- 1996-04-16 NZ NZ307236A patent/NZ307236A/xx unknown
- 1996-04-16 IN IN811DE1996 patent/IN185120B/en unknown
- 1996-04-16 PT PT96913594T patent/PT821697E/pt unknown
- 1996-04-16 HU HU9802942A patent/HUP9802942A3/hu unknown
- 1996-04-16 ES ES96913594T patent/ES2148759T3/es not_active Expired - Lifetime
- 1996-04-16 PL PL96322822A patent/PL322822A1/xx unknown
- 1996-04-16 JP JP53151096A patent/JP3856342B2/ja not_active Expired - Fee Related
- 1996-04-16 BR BR9604927A patent/BR9604927A/pt not_active Application Discontinuation
- 1996-04-16 DK DK96913594T patent/DK0821697T3/da active
- 1996-04-16 US US08/930,135 patent/US5789537A/en not_active Expired - Lifetime
- 1996-04-16 WO PCT/FR1996/000575 patent/WO1996033213A1/fr not_active Ceased
- 1996-04-16 CA CA002215991A patent/CA2215991A1/fr not_active Abandoned
- 1996-04-16 EP EP96913594A patent/EP0821697B1/fr not_active Expired - Lifetime
- 1996-04-16 TR TR97/01204T patent/TR199701204T1/xx unknown
- 1996-04-16 SK SK1404-97A patent/SK140497A3/sk unknown
- 1996-04-16 EA EA199700325A patent/EA000350B1/ru not_active IP Right Cessation
- 1996-04-16 CN CN96193360A patent/CN1181758A/zh active Pending
- 1996-04-16 AU AU56528/96A patent/AU708419B2/en not_active Ceased
- 1996-04-16 DE DE69609499T patent/DE69609499T2/de not_active Expired - Lifetime
- 1996-04-16 AP APAP/P/1997/001121A patent/AP768A/en active
- 1996-04-18 IL IL11796896A patent/IL117968A/xx active IP Right Grant
- 1996-04-18 TW TW085104644A patent/TW334437B/zh active
- 1996-04-18 ZA ZA963102A patent/ZA963102B/xx unknown
- 1996-04-18 AR ARP960102238A patent/AR002291A1/es unknown
-
1997
- 1997-10-14 NO NO974747A patent/NO974747D0/no not_active Application Discontinuation
- 1997-10-17 OA OA70108A patent/OA10525A/fr unknown
-
2000
- 2000-07-27 GR GR20000400169T patent/GR3033873T3/el not_active IP Right Cessation
-
2006
- 2006-07-24 JP JP2006201006A patent/JP2007031434A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1150943B1 (en) | Preparation of iodixanol | |
| EP0403351B2 (fr) | Procédé de préparation de l'acide ascorbique | |
| JPH08134055A (ja) | 3−o−置換アスコルビン酸の製造方法 | |
| JP3856342B2 (ja) | ストレプトグラミンの製造方法 | |
| KR20090119828A (ko) | 4,4´-(1-메틸-1,2-에탄디일)-비스-(2,6-피페라진디온)의 신규 제조 방법 | |
| EP1075480B1 (en) | Purification of carboxaldehyde | |
| US5847212A (en) | Process for the preparation of iohexol | |
| EP1951657B1 (en) | Process for the manufacture of iohexol | |
| US20130023681A1 (en) | Stabilized doxercalciferol and process for manufacturing the same | |
| US7476760B2 (en) | Purification and production methods of 1-aminocyclopropanecarboxylic acid | |
| EP1727784B1 (en) | Improved process for preparation of gabapentin | |
| KR100474228B1 (ko) | 파크리탁셀의분리방법 | |
| RU2179169C2 (ru) | Способ получения дигидрохлорида 2-трифторметил-10-[3-(1-метил-пиперазинил-4)-пропил]-фенотиазина | |
| RU2676304C1 (ru) | Способ получения лаппаконитин гидробромида | |
| MXPA97007749A (en) | Procedure for preparation of estreptogrami | |
| KR100483317B1 (ko) | α-페닐-α-프로폭시벤젠아세트산 1-메틸-4-피페리디닐에스테르 염산염의 제조방법 | |
| JP2001247549A (ja) | 1位置換ヒダントイン類の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070529 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070829 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071128 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080704 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080729 |